Compare Amphastar Pharmaceuticals Inc (AMPH) vs TJX Companies Inc (TJX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs TJX Companies Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while TJX Companies Inc trades at $151.45 (market cap $167.19B). The key difference: TJX Companies Inc is far larger — about 202.4× Amphastar Pharmaceuticals Inc's market cap, and TJX Companies Inc pays a 1.27% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | TJX | |
|---|---|---|
Market Cap | $826.08M | $167.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $168.41 |
52-Week Low | $16.87 | $121.35 |
Enterprise Value | $1.22B | $175.79B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
TJX trades at $151.34, showing modest daily gains amid a bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.19 versus $1.02 expected, and robust profitability metrics like a 61.25% ROE. Revenue growth is steady, climbing from $48.5B in 2022 to $56.4B in 2025, with further expansion projected. Recent news highlights TJX's resilience as a blue-chip retailer during market volatility, though technical indicators suggest near-term pressure.
The outlook for TJX remains positive based on fundamental strength and analyst optimism, with a consensus price target of $181.80 implying significant upside. Key opportunities include international expansion and same-store sales growth. Risks involve competitive retail pressures and macroeconomic sensitivity. Wall Street sentiment is overwhelmingly bullish, with 88% of analysts rating it a Buy, supporting a favorable long-term investment case despite short-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
